High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial
Higher semaglutide doses for type 2 diabetes and overweight or obesity provide modest additional glucose-lowering effect, with additional weight loss, at the expense of more AEs and treatment discontinuations. A study for evaluating high-dose semaglutide in obesity is currently underway.
Authors
- Ildiko Lingvay (ORCID: https://orcid.org/0000-0001-7006-7401)
- Vanita R. Aroda (ORCID: https://orcid.org/0000-0002-7706-4585)
- Anne Sofie Laulund (ORCID: https://orcid.org/0000-0002-4556-9968)
- Nils B. Jørgensen (ORCID: https://orcid.org/0000-0002-5764-6377)
- John B. Buse (ORCID: https://orcid.org/0000-0002-9723-3876)
- Bharath Kumar
Institutions
- University of North Carolina at Chapel Hill (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk (India) (IN)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Diabetes Care
- Published
- 2025-04-25
- DOI
- https://doi.org/10.2337/dc24-2425
- Citations
- 16
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 20.72
Funders
- American Diabetes Association
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Regeneron Pharmaceuticals
- Vertex Pharmaceuticals
- Insulet Corporation
- MannKind Corporation
- Dexcom
- Tandem Diabetes Care
- Moderna
- Novo Nordisk
- Shionogi
- Servier
- National Institutes of Health
- University of North Carolina at Chapel Hill
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences